In Allergan USA v. MSN Labs, the US Court of Appeals for the Federal Circuit held, that later-filed, later-issued claims cannot serve as proper reference for invalidating earlier-filed, earlier-issued claims having the same...more
Pharmaceutical drug pricing and reimbursement remains a bipartisan focus as we draw closer to the November presidential elections, with politicians remaining steadfast in their efforts to turn up the heat on pharmaceutical...more
The PTAB Digest 2021/2022 provides an overview of PTAB statistics, trends, and updates that impact strategies and business decisions for patent owners and petitioners alike.
Significant developments included the...more
EU – REGULATORY -
Brexit, Notified Bodies, and Medical Devices -
The House of Commons Library published a briefing paper on June 12 on the UK’s product standards and safety marking compliance in light of Brexit. In the...more
8/20/2019
/ Anti-Kickback Statute ,
Asia ,
China ,
Competition ,
Data Privacy ,
Drug Pricing ,
EU ,
Food and Drug Administration (FDA) ,
Intellectual Property Protection ,
Life Sciences ,
Medical Devices ,
Patents ,
Pharmaceutical Industry ,
UK Brexit
UK authorities have recently released statements on how patents, trade marks, Community designs, and copyright will be handled if the United Kingdom and the European Union fail to reach a deal before Brexit....more
Pharmaceutical and agricultural companies in particular should consider the effect of Brexit on their European patent portfolios.
Supplementary Protection Certificates (SPCs) are governed by EU regulations and are thus...more
7/7/2016
/ Agricultural Sector ,
EU ,
Intellectual Property Protection ,
Member State ,
Patent Portfolios ,
Patents ,
Pharmaceutical Industry ,
Popular ,
Referendums ,
Supplementary Protection Certificate ,
UK ,
UK Brexit ,
UK Patent Act